ENV-308

all catalysts(0)

nothing on the calendar yet

News(5)

• Enveda, an AI drugmaker, banks $311M in venture funding
  Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.
  biopharma_dive · 10d ago
• AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
  Tech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.
  biospace · 10d ago
• Enveda reaps $311M series E to feed ambition to become a ‘household name’
  Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.
  fiercebiotech · 10d ago
• Enveda’s exercise-simulating obesity tablet clears early clinical test
  Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
  biospace · 1mo ago
• STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
  Colorado biotech Enveda reports preliminary results on a drug to help people maintain weight loss after GLP-1 use. Just don't call it exercise in a pill.
  stat · 1mo ago